In conclusion, our results indicate that the over-expression of HDAC6 is a favorable prognostic marker in the HGSOC ovarian cancer subtype and highlights HDAC6 as a potential therapeutic target for HGSOC. This evidence concerns the gene HDAC6 and ovarian cancer.